Drug Repurposing Innovative Approaches to Drug Discovery and Development /
This book offers an insightful exploration of drug repurposing, an innovative approach to drug discovery and development that has the potential to revolutionize the field of medicine. It begins with an introduction to drug repurposing and its history, providing a comprehensive overview of the subjec...
Salvato in:
| Ente Autore: | |
|---|---|
| Altri autori: | , , |
| Natura: | Elettronico eBook |
| Lingua: | inglese |
| Pubblicazione: |
Singapore :
Springer Nature Singapore : Imprint: Springer,
2024.
|
| Edizione: | 1st ed. 2024. |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1007/978-981-97-5016-0 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-981-97-5016-0 | ||
| 003 | DE-He213 | ||
| 005 | 20260810154316.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 240829s2024 si | o |||| 0|eng d | ||
| 020 | |a 9789819750160 |9 978-981-97-5016-0 | ||
| 024 | 7 | |a 10.1007/978-981-97-5016-0 |2 doi | |
| 050 | 4 | |a RS199.5 | |
| 072 | 7 | |a TCB |2 bicssc | |
| 072 | 7 | |a SCI010000 |2 bisacsh | |
| 072 | 7 | |a TCB |2 thema | |
| 082 | 0 | 4 | |a 615.6 |2 23 |
| 245 | 1 | 0 | |a Drug Repurposing |h [electronic resource] : |b Innovative Approaches to Drug Discovery and Development / |c edited by Naveen Chella, Om Prakash Ranjan, Amit Alexander. |
| 250 | |a 1st ed. 2024. | ||
| 264 | 1 | |a Singapore : |b Springer Nature Singapore : |b Imprint: Springer, |c 2024. | |
| 300 | |a 1 online resource (XIII, 248 p. 34 illus.). |b 33 illus. in color. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 341 | 0 | |b Table of contents navigation |2 onix | |
| 341 | 0 | |b Single logical reading order |2 onix | |
| 341 | 0 | |b Short alternative textual descriptions |2 onix | |
| 341 | 0 | |b Use of color is not sole means of conveying information |2 onix | |
| 341 | 0 | |b Use of high contrast between text and background color |2 onix | |
| 341 | 0 | |b Next / Previous structural navigation |2 onix | |
| 341 | 0 | |b All non-decorative content supports reading without sight |2 onix | |
| 347 | |a text file |b PDF |2 rda | ||
| 505 | 0 | |a Chapter 1. Drug repurposing: History, Significance, Benefits, Approaches and Challenges -- Chapter 2. Methodologies Adopted in Drug Repurposing -- Chapter 3. In silico methods used in drug repurposing -- Chapter 4. Role of artificial and machine learning in drug repurposing -- Chapter 5. Drug repurposing in cancer therapy -- Chapter 6. Drug repurposing in inflammatory disorders -- Chapter 7. Drug repurposing in CNS disorders -- Chapter 8. Reshaping the Therapeutic Landscape: Drug Repurposing for Emerging Infectious Diseases and Rare Diseases -- Chapter 9. Clinical trials on repurposed drugs: an overview -- Chapter 10. Intellectual Property Rights and Regulatory Considerations Throughout Drug Repurposing -- Chapter 11. Redirection to the Drug Discovery: Antidiabetic Drugs Repurposing in Cancer. | |
| 520 | |a This book offers an insightful exploration of drug repurposing, an innovative approach to drug discovery and development that has the potential to revolutionize the field of medicine. It begins with an introduction to drug repurposing and its history, providing a comprehensive overview of the subject. The readers will embark on a journey through the diverse landscape of drug repurposing strategies. From in silico methods of predicting drug-disease associations to experimental approaches to the integrations of artificial intelligence (AI) and machine learning (ML) in drug repurposing for validating repurposed candidates. The book also delves into the application of drug repurposing in various disease areas, including cancer, inflammatory disorders, and CNS disorders. It explores the potential hurdles involved in the regulatory aspects of the process. The book further covers drug products under clinical trials and provides an overview of the future perspectives of drug repurposing. With its detailed and informative content, this book is a must-read for researchers, clinicians, and healthcare professionals interested in the exciting field of drug repurposing. | ||
| 532 | 8 | |a Accessibility summary: This PDF does not fully comply with PDF/UA standards, but does feature limited screen reader support, described non-text content (images, graphs), bookmarks for easy navigation and searchable, selectable text. Users of assistive technologies may experience difficulty navigating or interpreting content in this document. We recognize the importance of accessibility, and we welcome queries about accessibility for any of our products. If you have a question or an access need, please get in touch with us at accessibilitysupport@springernature.com. | |
| 532 | 8 | |a No reading system accessibility options actively disabled | |
| 532 | 8 | |a Publisher contact for further accessibility information: accessibilitysupport@springernature.com | |
| 588 | |a Print version record. | ||
| 650 | 0 | |a Drug delivery systems. | |
| 650 | 0 | |a Pharmacovigilance. | |
| 650 | 0 | |a Diseases. | |
| 650 | 1 | 4 | |a Drug Delivery. |
| 650 | 2 | 4 | |a Drug Safety and Pharmacovigilance. |
| 650 | 2 | 4 | |a Diseases. |
| 700 | 1 | |a Chella, Naveen. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Ranjan, Om Prakash. |e editor. |0 (orcid)0000-0003-1833-5207 |1 https://orcid.org/0000-0003-1833-5207 |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Alexander, Amit. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9789819750153 |
| 776 | 0 | 8 | |i Printed edition: |z 9789819750177 |
| 776 | 0 | 8 | |i Printed edition: |z 9789819750184 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-981-97-5016-0 |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||